Clinical Trial Update: A Safety and Efficacy Study of JNJ26489112 in Patients With Treatment-Resistant Major Depressive Disorder [Phase 2]

View source ↗

Summary

A Phase 2 safety and efficacy study of JNJ26489112 in treatment-resistant major depressive disorder was terminated. No results are provided in this update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• JNJ26489112

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Depression | Phase 2 | Status: TERMINATED